SALE OF SEVERN TRENT LABORATORIES(US)
Severn Trent Plc announces today the sale of its US analytical environmental
testing firm Severn Trent Laboratories (STL) to TestAmerica Holdings, an
affiliate of H.I.G. Capital, for a cash consideration of approximately £85
million.
The transaction is subject to US regulatory approval and is expected to be
completed by the end of December 2006. STL UK will remain part of the Severn
Trent group.
Mr Colin Matthews, Group Chief Executive, said "We announced in June that
following our decision to demerge Biffa we wanted to concentrate on water.
Therefore STL US was no longer regarded as core. Today's announcement continues
our strategic drive to create value through a focus on water."
STL Chief Executive Officer Rachel Brydon Jannetta will remain with STL US and
resign from the Severn Trent Plc Board on completion of the deal.
For further information contact:
Peter Gavan 02476 656114
Director of Corporate Affairs 07901 517447
Jonathan Davies
Head of Investor Relations 0121 722 4295
David Trenchard
Tulchan Communications Group 020 7353 4200
www.severntrent.com
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.